Privileged structure-based quinazolinone natural product-templated libraries: Identification of novel tubulin polymerization inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 3, 2006, Pages 686-690

  Liu, Ji Feng ^a   Wilson, Christopher J ^a   Ye, Ping ^a   Sprague, Kevin ^a   Sargent, Katie ^a   Si, Ying ^a   Beletsky, Galina ^a   Yohannes, Daniel ^a   Ng, Shi Chung ^a  

^a ARQULE INC   (United States)

Author keywords

Natural product templated library; Privileged structure; Quinazolinone; Tubulin polymerization inhibitors

Indexed keywords

ANTIMITOTIC AGENT; BENZODIAZEPINE DERIVATIVE; ISAINDIGOTONE; MACKINAZOLINONE; PACLITAXEL; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; POLYMERIZATION;

ANIMALS; ANTIMITOTIC AGENTS; BINDING SITES; BIOLOGICAL PRODUCTS; DRUG DESIGN; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUMOR CELLS, CULTURED;

EID: 29544449697     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.10.022     Document Type: Article

References (39)

1. According to Evans, a privileged structure is 'a single molecular framework able to provide ligands for diverse receptors,' see: B.E. Evans, K.E. Rittle, M.G. Bock, R.M. DiPardo, R.M. Freidinger, W.L. Whitter, G.F. Lundell, D.F. Veber, P.S. Anderson, R.S.L. Chang, V.J. Lotti, D.J. Cerino, T.B. Chen, P.J. Kling, K.A. Kunkel, J.P. Springer, and J. Hirshfield J. Med. Chem. 31 1988 2235
2. D.A. Horton, G.T. Bourne, and M.L. Smythe Chem. Rev. 103 2003 893
3. R.W. DeSimone, K.S. Currie, S.A. Mitchell, J.W. Darrow, and D.A. Pippin Comb. Chem. High Throughput Screening 7 2004 473
4. For recent reviews on quinazoline alkaloids, see: J.P. Michael Nat. Prod. Rep. 21 2004 650
5. S. Johne M.F. Ansell Supplements to the 2nd Edition of Rodd's Chemistry of Carbon Compounds Vol. IV I/J 1995 Elsevier Amsterdam 223
6. Z. Ma, Y. Hano, T. Nomura, and Y. Chen Heterocycles 46 1997 541
7. A. Cagir, S.H. Jones, R. Gao, B.M. Eisenhauer, and S.M. Hecht J. Am. Chem. Soc. 125 2003 13628
8. H. Wang, and A. Ganesan J. Org. Chem. 65 2000 1022
9. S. Sinha, and M. Srivastava Prog. Drug Res. 43 1994 143
10. P. Molina, A. Tárraga, A. Gonzalez-Tejero, I. Rioja, A. Ubeda, M.C. Terencio, and M.J. Alcaraz J. Nat. Prod. 64 2001 1297
11. S.E. de Laszlo, C.S. Quagliato, W.J. Greenlee, A.A. Patchett, R.S.L. Chang, V.J. Lotti, T.-B. Chen, S.A. Scheck, K.A. Faust, S.S. Kivlighn, T.S. Schorn, G.J. Zingaro, and P.K.S. Siegl J. Med. Chem. 36 1993 3207
12. A.H. Amin, and D.R. Mehta Nature 183 1959 1317
13. D.R. Mehta, J.S. Naravane, and R.M. Desai J. Org. Chem. 28 1963 445
14. M.P. Jain, S.K. Koul, K.L. Dhar, and C.K. Atal Phytochemistry 19 1980 1880
15. A. Al-Shamma, S. Drake, D.L. Flynn, L.A. Mitscher, Y.H. Park, G.S.R. Rao, A. Simpson, J.K. Swayze, T. Veysoglu, and S.T.S. Wu J. Nat. Prod. 44 1981 745
16. Koizumi, M.; Matsuura, I.; Murakami, Y. Japan Kokai 77 77, 093, 1977; Chem. Abstr. 1978, 88, 6930s.
17. J.-F. Liu, P. Ye, K. Sprague, K. Sargent, D. Yohannes, C.M. Baldino, C.J. Wilson, and S.-C. Ng Org. Lett. 7 2005 3363
18. J.-F. Liu, P. Ye, B. Zhang, G. Bi, K. Sargent, L. Yu, D. Yohannes, and C.M. Baldino J. Org. Chem. 70 2005 6339
19. Liu, J.-F.; Kaselj, M.; Isome, Y.; Chapnick, J.; Zhang, B.; Bi, G.; Yohannes, D.; Yu, L.; Baldino, C. M. J. Org. Chem., in press (jo051876x).
20. MTS assay was performed as described in Promega Technical Bulletin No. 169 (CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay, http://www.promega.com /). The assay uses the novel tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) -2H-tetrazolium, inner salt; MTS) and the electron coupling reagent, phenazine methosulfate (PMS). MTS is chemically reduced by cells into formazan, which is soluble in tissue culture medium. The measurement of the absorbance of the formazan can be carried out using 96-well microplates at 492 nm. The assay measures dehydrogenase enzyme activity found in metabolically active cells.
21. G. Doria, C. Passarotti, R. Magrini, R. Sala, P. Sberze, M. Tibolla, G. Arcari, and R. Castello Farmaco 39 1984 968
22. 2-Aryl, as well as 3H and 3-heterocyclo substituted 2-styrylquinazolin-4- ones, have been reported to be cytotoxic agents which inhibit tubulin polymerization. See: D. Raffa, M.C. Edler, G. Daidone, B. Maggio, M. Merickech, S. Plescia, D. Schillaci, R. Bai, and E. Hamel Eur. J. Med. Chem. 39 2004 299
23. Y. Xia, Z.-Y. Yang, M.-J. Hour, S.-C. Kuo, P. Xia, K.F. Bastow, Y. Nakanishi, P. Nampoothiri, T. Hackl, E. Hamel, and K.H. Lee Bioorg. Med. Chem. Lett. 11 2001 1193
24. J.B. Jiang, D.P. Hesson, B.A. Dusak, D.L. Dexter, G.J. Kang, and E. Hamel J. Med. Chem. 33 1990 1721
25. The high content screening of the repository libraries including the quinazolinone library assay has been reported, see Wilson, C. J.; Si, Y.; Thompson, C. M.; Smellie, A.; Ashwell, M. Liu, J.-F.; Ye, P.; Yohannes, D.; Ng, S.-C. J. Biomol. Screen., in press.
26. J.-F. Liu, J. Lee, A.M. Dalton, G. Bi, L. Yu, C.M. Baldino, E. McElory, and M. Brown Tetrahedron Lett. 46 2005 1241
27. The in-house developed library design tool we used, MAPMAKER, has been described: Li, D.; Rotstein, S. Abstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004, CINF-98.
28. C.M. Baldino, J. Caserta, W.K. Goetzinger, M. Harris, D. Hartsough, D. Yohannes, L. Yu, and J.N. Kyranos Curr. Drug Discov. 7 2004 15
29. For the design of libraries possessing maximal information of content and diversity, see: Patterson, J. E.; Zhang, Y.; Smellie, A.; Li, D.; Hartsough, D. S.; Yu, L.; Baldino, C. M. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005, CINF-75.
30. We employed a Biotage Smith Synthesizer™ integrated into the ArQule AMAP™ platform.
31. J.N. Kyranos, H. Cai, B. Zhang, and W.K. Goetzinger Curr. Opin. Drug Discov. Devel. 4 2001 719
32. W. Goetzinger, X. Zhang, G. Bi, M. Towle, D. Cherrak, and J.N. Kyranos Int. J. Mass. Spectrom. 238 2004 153
33. M.A. Jordan, and L. Wilson Nat. Rev. Cancer 4 2004 253
34. D.T. Miyamoto, Z.E. Perlman, T.J. Mitchison, and M. Shirasu-Hiza Prog. Cell Cycle Res. 5 2003 349
35. K.W. Wood, W.D. Cornwell, and J.R. Jackson Curr. Opin. Pharmacol. 1 2001 370
36. F. Hans, and S. Dimitrov Oncogene 20 2001 3021
37. Refs. 17-19.
38. S.M. Wignall, N.S. Gray, Y.T. Chang, L. Juarez, R. Jacob, A. Burlingame, P.G. Schultz, and R. Heald Chem. Biol. 11 2004 135
39. S.K. Tahir, E. Han, B. Credo, H.S. Jae, J.A. Pietenpol, C.D. Scatena, J.R. Wu-Wong, D. Frost, H. Sham, S.H. Rosenberg, and S.-C. Ng Cancer Res. 61 2001 5480